Manufacturer recalls antidepressant for poor dissolution rate

Patients in Philadelphia will typically take any medications that they’re counseled to take without any reservations. After all, there are safeguards and standards in place to ensure that unsafe drugs are not released to market, right? What many don’t understand is the complex chemistry behind the drugs that they are taking. The smallest error in the composition of the drug may have a dramatic effect on its intended performance once it’s been taken. Often, those errors are difficult to pinpoint initially. If and when they finally do surface, federal standards will often require that the manufacturer issue a product recall.

A specific lot of medication meant for the treatment of depression was recently recalled by its manufacturer. The recalled supply of meds was created at a plant in India and distributed through the manufacturer’s American affiliate. The issue behind the recall has to do with the design of the tablets themselves. Intended as an extended-release treatment, the manufacturer found that the tablet dissolution rate did not meet the standard set by the drug release dissolution specifications.

In this case, the recall issued was of a “Class II” classification, meaning that the probability of serious, irreversible health consequences in those who took the drug were remote. However, any liability issues that the makers of dangerous drugs may be subject to are often not determined by the seriousness of the consequences that those exposed to them may face. Anyone whose health or well-being has suffered as the result of a defective drug may have cause to initiate action against the drug’s manufacturer. Those looking to pursue such action may benefit from the assistance of a personal injury attorney.

Source: Reuters “India’s Sun Pharma recalls over 40,000 bottles of antidepressant” July 11, 2014

Leave a Reply

Your email address will not be published. Required fields are marked *